These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 16541725)

  • 1. [Progress and perspectives in the treatment of systemic lupus erythematosus].
    Robak E; Sysa-Jedrzejowska A; Wozniacka A
    Przegl Lek; 2005; 62(9):894-9. PubMed ID: 16541725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition and management of systemic lupus erythematosus.
    Schroeder JO; Euler HH
    Drugs; 1997 Sep; 54(3):422-34. PubMed ID: 9279504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for juvenile-onset systemic lupus erythematosus.
    Carreño L; López-Longo FJ; González CM; Monteagudo I
    Paediatr Drugs; 2002; 4(4):241-56. PubMed ID: 11960513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer drugs for the treatment of lupus nephritis.
    Kuiper-Geertsma DG; Derksen RH
    Drugs; 2003; 63(2):167-80. PubMed ID: 12515564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy of SLE].
    Nakazawa T; Kumagai S; Kogata Y
    Nihon Rinsho; 2005 May; 63 Suppl 5():253-9. PubMed ID: 15954358
    [No Abstract]   [Full Text] [Related]  

  • 7. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH; Chan TM
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pragmatic approaches to therapy for systemic lupus erythematosus.
    Xiong W; Lahita RG
    Nat Rev Rheumatol; 2014 Feb; 10(2):97-107. PubMed ID: 24166241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of lupus nephritis.
    Jaryal A; Vikrant S
    Indian J Med Res; 2017 Feb; 145(2):167-178. PubMed ID: 28639592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity.
    Robak E; Robak T
    Curr Med Chem; 2012; 19(3):438-53. PubMed ID: 22335517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.
    Karim MY; Alba P; Cuadrado MJ; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR
    Rheumatology (Oxford); 2002 Aug; 41(8):876-82. PubMed ID: 12154204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil and systemic lupus erythematosus: an overview.
    Pisoni CN; Karim Y; Cuadrado MJ
    Lupus; 2005; 14 Suppl 1():s9-11. PubMed ID: 15803925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.
    Chang HK
    J Korean Med Sci; 2005 Oct; 20(5):883-5. PubMed ID: 16224167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severe lupus nephritis: the new horizon.
    Chan TM
    Nat Rev Nephrol; 2015 Jan; 11(1):46-61. PubMed ID: 25421826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].
    Harboe E; Gøransson L; Wildhagen K; Omdal R
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1650-2. PubMed ID: 15976831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging lupus treatments.
    Wallace D
    Am J Manag Care; 2001 Oct; 7(16 Suppl):S490-5. PubMed ID: 11680781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive fungal infections in Argentine patients with systemic lupus erythematosus.
    Vinicki JP; Catalan Pellet S; Pappalardo C; Cruzat VC; Spinetto MA; Dubinsky D; Tiraboschi IN; Laborde HA; Nasswetter G
    Lupus; 2013 Aug; 22(9):892-8. PubMed ID: 23861029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.
    Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S
    Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment strategies for proliferative lupus nephritis: keep children in mind!
    Ranchin B; Fargue S
    Lupus; 2007; 16(8):684-91. PubMed ID: 17711908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
    de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
    Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.